Stock Details
MRK is Merck & Co., Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 76.86$. Average daily volumn in 3 months 12.13M. Market cap 197.12B



Stock symbol : MRK. Exchange : NYSE. Currency : USD
Lastest price : 77.85$. Total volume : 7.92M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Merck & Co., Inc. (MRK)
Last Price
77.85$
Change
0.61
Volume
7.92M

Previous Close77.24
Open77.46
Day Range76.74-78.12
Bid0.00 x 900
Ask0.00 x 800
Volume7.92M
Average Volume12.13M
Market Cap197.12B
Beta0.42
52 Week Range68.44-83.78
Trailing P/E28.11
Foward P/E11.85
Dividend (Yield %)3.37%
Ex-Dividend Date2021-06-14



Financial Details


According to Merck & Co., Inc.'s financial reports the company's revenue in 2020 were 47.99B an increase( +2.17%) over the years 2019 revenue that were of 46.84B. In 2020 the company's total earnings were 7.07B while total earnings in 2019 were 9.84B(-22.22%).


Loading ...



Organization

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.

Merck & Co., Inc._logo

Market Cap:
197.12B
Revenue:
47.99B
Total Assets:
91.59B
Total Cash:
8.06B


News about "Merck & Co., Inc."

Price Over Earnings Overview: Merck & Co_image

Price Over Earnings Overview: Merck & Co

In the current session, Merck & Co Inc. (NYSE:MRK) is trading at $77.56, after a 0.41% increase. Over the past month, the stock increased by 0.45%, and in ...

Source from : Benzinga.com - 1 days ago


Merck (MRK) to Report Q2 Earnings: What's in the Cards?_image

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Merck MRK will report second-quarter 2021 results on Jul 29 before market open. In the last-reported quarter, the company delivered a negative earnings surprise of 14.11%. The large drugmaker’s ...

Source from : YAHOO!Finance - 2 days ago


Merck & Co. Inc. (NYSE: MRK) Has Been Trading Down. What Are The Prospects For The Future?

Merck & Co. Inc. (NYSE:MRK) traded at $77.54 at close of the session on Friday, 07/23/21, made an upward move of 1.32% on its previous day’s price. Looking at the stock we see that its previous close ...

Source from : stocksregister - 2 days ago


Merck Announces Fourth-Quarter 2021 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.65 per share of the company’s common stock for ...

Source from : Business Wire - 20 hours ago


Merck : Phase 3 Trial On Metastatic Triple-Negative Breast Cancer Meets Primary Endpoint_image

Merck : Phase 3 Trial On Metastatic Triple-Negative Breast Cancer Meets Primary Endpoint

Merck & Co., Inc. (MRK) said that a phase 3 KEYNOTE-355 trial met primary endpoint of overall survival in patients with metastatic triple-negative breast cancer or mTNBC whose tumors expressed PD-L1.

Source from : Nasdaq - 1 days ago


Merck Launches New Green Solvents for Photoresist Removal in Chip Production_image

Merck Launches New Green Solvents for Photoresist Removal in Chip Production

Merck, a leading science and technology company, today announced the launch of a new line of complementary green solvents for use in photolithographic processes in semiconductor manufacturing. The ...

Source from : Business Insider - 1 days ago


U.S. FDA approves Merck's Keytruda combo for early breast cancer treatment_image

U.S. FDA approves Merck's Keytruda combo for early breast cancer treatment

The FDA approval is for treating triple-negative breast cancer (TNBC), an aggressive form of the disease with an increased risk of recurrence. Trial data from over 1,000 patients showed that the drug, ...

Source from : YAHOO!News - 1 days ago


Precision Medicine Software Market to Witness Robust Expansion by 2027 | Merck & Co., Inc, Translational Software, Inc_image

Precision Medicine Software Market to Witness Robust Expansion by 2027 | Merck & Co., Inc, Translational Software, Inc

The global market for precision medicine software is expected to register substantial growth in the near future due to increased collaboration between research institutions and companies increased lic ...

Source from : Big News Network.com - 1 days ago


FDA Approves Merck's KEYTRUDA To Treat High-Risk Early-Stage Triple-Negative Breast Cancer_image

FDA Approves Merck's KEYTRUDA To Treat High-Risk Early-Stage Triple-Negative Breast Cancer

The U.S. Food and Drug Administration has approved Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA, for the treatment of patients with high-risk early-stage triple-negative breast cancer or TNBC ...

Source from : Nasdaq - 1 days ago


Merck rebounds to win a milestone immunotherapy approval in early breast cancer

The FDA reversed an earlier decision to make Keytruda the first immunotherapy available for patients with early-stage breast cancer and also gave the drugmaker a full approval in advanced disease.

Source from : BioPharma Dive - 1 days ago


Company Of The Day: Merck_image

Company Of The Day: Merck

The U.S. FDA approved a new version of Merck's (NYSE:MRK) pneumococcal vaccine that prevents invasive disease caused by 15 strains of bacteria called Streptococcus ...

Source from : Forbes - 8 days ago


Covid-19 pill race heats up as Japanese firm vies with Pfizer, Merck_image

Covid-19 pill race heats up as Japanese firm vies with Pfizer, Merck

A Japanese company has started human trials of the first once-a-day pill for Covid-19 patients, joining Pfizer Inc. and Merck & Co. in the race to find treatments for the disease.

Source from : Fox Business - 2 days ago


Yellow Fever Market to Explore Excellent Growth in Future : Pfizer, Glaxosmithkline, Merck_image

Yellow Fever Market to Explore Excellent Growth in Future : Pfizer, Glaxosmithkline, Merck

The Global Yellow Fever Market outlook survey highlights the dynamics at play in each of the subsegments of Yellow Fever Industry to better elaborate current state, emerging trends and potential areas ...

Source from : SBWire - 1 days ago


Merck's Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA's prior reluctance_image

Merck's Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA's prior reluctance

The FDA had reservations about Merck & Co.’s proposed use of Keytruda around surgery for patients with early triple-negative breast cancer. But less than three months after seeing additional clinical ...

Source from : FiercePharma - 1 days ago


Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance_image

Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance

Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Source from : YAHOO!Finance - 9 days ago


Domino's, Eli Lilly, McDonald's, Merck and More Tuesday Afternoon Analyst Upgrades and Downgrades_image

Domino's, Eli Lilly, McDonald's, Merck and More Tuesday Afternoon Analyst Upgrades and Downgrades

Wall St. is reviewing some big analyst calls seen on Tuesday. We have included the latest analyst call on each stock, as well as a recent trading history and the consensus targets among analysts. For ...

Source from : 24/7 Wall St - 1 days ago


Merck's Keytruda Hits Key Endpoint in Metastatic Triple-Negative Breast Cancer

Merck & Co. Tuesday said a pivotal Phase 3 study of its cancer drug Keytruda in combination with chemotherapy met a primary endpoint of overall survival in metastatic triple-negative breast cancer.

Source from : Morningstar, Inc. - 1 days ago


The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts_image

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ...

Source from : Benzinga.com on MSN.com - 1 days ago


Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe_image

Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe

Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.

Source from : YAHOO!News - 6 days ago


FDA approves Merck's Keytruda as breast cancer treatment

The Food and Drug Administration (FDA) approved Merck’s immunotherapy Keytruda for early treatment of triple-negative breast cancer (TNBC) in combination with chemotherapy, the pharmaceutical company ...

Source from : The Hill on MSN.com - 1 days ago


Merck's Keytruda Hits Key Endpoint in Metastatic Triple-Negative Breast Cancer >MRK

Merck said Keytruda is the first anti-PD-1 therapy in combination with chemotherapy to show statistically significant overall survival for that patient population. The company previously reported that ...

Source from : MarketWatch - 1 days ago


Why Merck & Co. Inc. (NYSE: MRK) Stock Shouldn’t Be Ignored In 2021_image

Why Merck & Co. Inc. (NYSE: MRK) Stock Shouldn’t Be Ignored In 2021

In today’s recent session, 2.74 million shares of the Merck & Co. Inc. (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share price was $77.03, and it changed around -$0.

Source from : marketingsentinel - 7 days ago


Roll up the Sleeves! When the bell rang at previous close Merck & Co. Inc. (MRK) was down -1.24%_image

Roll up the Sleeves! When the bell rang at previous close Merck & Co. Inc. (MRK) was down -1.24%

At the end of the latest market close, Merck & Co. Inc. (MRK) was valued at $78.02. In that particular session, Stock kicked-off at the price of $77.81 while reaching the peak value of $78.3384 and ...

Source from : investchronicle - 8 days ago


Merck & Co. Inc. (NYSE: MRK) Received An -1.13% Loss In 6 Months – Here’s What To Expect

During the recent session, Merck & Co. Inc. (NYSE:MRK)’s traded shares were 1.66 million, with the beta value of the company hitting 0.42. At the last check today, the stock’s price was $77.11, ...

Source from : marketingsentinel - 5 days ago


Biotech company seeks $85M in incentives for north St. Louis County expansion_image

Biotech company seeks $85M in incentives for north St. Louis County expansion

A biotechnology company is asking St. Louis County for public incentives to help fund an expansion of its north St. Louis County campus. Patheon Biologics, a subsidiary of Massachusetts-based Thermo ...

Source from : St. Louis Post-Dispatch - 1 days ago


Merck looks to overturn FDA's Keytruda rebuff with updated triple-negative breast cancer data_image

Merck looks to overturn FDA's Keytruda rebuff with updated triple-negative breast cancer data

After an embarrassing admonition from the FDA, Merck & Co. has returned with updated Keytruda data it hopes will change the regulators’ mind on approval in early triple-negative breast cancer.

Source from : FiercePharma - 13 days ago


Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895–1995

It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.' John Hunt, The Pharmaceutical Journal ...

Source from : Cambridge University Press - 1 days ago


Merck Says Verquvo Granted Marketing Authorization in European Union

By Michael Dabaie Merck & Co. Inc. said the European Commission granted marketing authorization for Verquvo to Bayer AG. In the EU, Verquvo is ...

Source from : MarketWatch - 7 days ago


IAS: Merck’s long-acting HIV med hits protective levels in phase 2_image

IAS: Merck’s long-acting HIV med hits protective levels in phase 2

Two dose levels of Merck's drug, islatravir, quickly reached protective levels in the blood of adults at low risk of contracting HIV-1, the most widespread type of HIV. The drug also stayed at those ...

Source from : FierceBiotech - 8 days ago


Global Portable Bioprocessing Bioreactors Market Technology Prospectus to 2027 – Merck & Co. Inc., IKA, GE Healthcare, Thermo Fisher Scientific_image

Global Portable Bioprocessing Bioreactors Market Technology Prospectus to 2027 – Merck & Co. Inc., IKA, GE Healthcare, Thermo Fisher Scientific

Request Sample is Available @ The global Portable Bioprocessing Bioreactors Market is anticipated to reach the market size of xx million USD in 2026 from xx million USD in 2020 by registering a CAGR ...

Source from : manometcurrent.com - 9 days ago


Merck's Keytruda Nets Two FDA Full Approvals in Triple-Negative Breast Cancer

The PD-1 inhibitor is now approved as neoadjuvant and adjuvant therapy for high-risk early-stage TNBC, as well as for later-stage, PD-L1-high TNBC patients with chemo.

Source from : precisiononcologynews - 1 days ago


Global Telemedicine Market Market Report 2021-21026 with Analysis of CEVA, Inc, Eli Lilly and Co, Bayer AG, Merck & Co, Teladoc Health, Inc.

The "Telemedicine Market, Global Forecast Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Financial Insight" report has been added to ResearchAndMarkets.com's offering.

Source from : Business Insider - 6 days ago


ParkinsonÕs Disease Drugs Market 2021: Comprehensive Research Including Top Companies like-Merck & Co. Inc., Impax Laboratories Inc

Source=OpenPR&Mode=AK Top Leading Companies of ParkinsonÕs Disease Drugs Market are Merck & Co. Inc., Impax Laboratories Inc., AbbVie Inc., Mylan NV, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, M ...

Source from : openpr.com - 13 days ago


Sickle Cell Disease Treatment Market Size, Share 2021-2028 | Top Key Vendors – Pfizer Inc., Eli Lilly, Merck & Co Inc, Novartis AG, Sanofi, Baxter_image

Sickle Cell Disease Treatment Market Size, Share 2021-2028 | Top Key Vendors – Pfizer Inc., Eli Lilly, Merck & Co Inc, Novartis AG, Sanofi, Baxter

The Sickle Cell Disease Treatment Market study provides details of market dynamics affecting the market, market size, and segmentation, and casts a shadow over the major market players by highlighting ...

Source from : manometcurrent.com - 13 days ago


Merck Announces Appointment of Head of China & International for Healthcare_image

Merck Announces Appointment of Head of China & International for Healthcare

Merck, a leading science and technology company, today announced that Hong Chow will join its Healthcare business sector as Head of China & International on October 1. In this role at Merck, Chow will ...

Source from : 아크로팬 - 5 days ago


Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29

During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call on ...

Source from : Business Wire - 28 days ago


5 Best Medical Stocks to Invest In

Merck & Co., Inc. (NYSE: MRK) is fifth on our list of best medical stocks to invest in. It is an American pharmaceutical company manufacturing medicines for some life-threatening diseases ...

Source from : Insider Monkey - 27 days ago


Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy

a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced a new survey 1 that unveils the support dog and cat owners are seeking as the country reopens following the COVID ...

Source from : PR Newswire - 20 days ago


Merck and B. Braun Join Forces in the Development of Bioelectronic Devices

Braun and neuroloop, we aim to create novel modalities to enhance the quality of care for patients in several chronic diseases,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “In ...

Source from : PharmiWeb - 28 days ago


The Coronavirus Pill Makes Merck a Solid Buy

I am bullish on the stock and believe that the company will be able to cash in on the coronavirus pill this year. Pharma stocks are hot picks currently and there is a lot going right for Merck.

Source from : InvestorPlace - 20 days ago


Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

They spun it off to try to have the rest of Merck grow quicker, so I think it's probably one of those things where hopefully they maybe they pay a dividend and that's the type of company that you ...

Source from : The Motley Fool - 16 days ago


Mizuho: Merck withdrawing Keytruda as a gastric cancer treatment won't impact the stock

Shares of Merck & Co. Inc. (MRK) were up 0.7% in trading on Friday, the day after the company said it will voluntarily withdraw an accelerated approval for Keytruda as a third-line treatment for ...

Source from : Morningstar%2c Inc. - 26 days ago


Merck to Withdraw Indication for Pembrolizumab in Third Line Gastric Cancer

The accelerated approval indication for pembrolizumab (Keytruda) in patients with gastric cancer in the third-line setting will be voluntarily withdrawn by Merck, the pharmaceutical company ...

Source from : Cancer Network - 20 days ago


Merck KGaA wants to optimize 'highly complex' manufacturing process with new biotech center

Merck already has significant development activities in the Central European country, including eight established locations. The company thinks the Lake Leman region will also provide a highly ...

Source from : FierceBiotech - 20 days ago


Merck’s new CEO Robert Davis begins, after Ken Frazier's retirement

Pharmaceutical giant Merck, which boasts some of the world's best-selling drugs, has a new CEO to lead the company. Robert Davis became chief executive officer of Merck on Thursday, one day ...

Source from : Fox Business - 27 days ago


The Globe and Mail

During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call on ...

Source from : The Globe and Mail - 28 days ago


Merck signs MoU with African Federation of Fertility Societies

JOHANNESBURG, South Africa-/African Media Agency(AMA)/- Merck, a leading science and technology company, today announced the signature of a Memorandum of Understanding (MoU) with the African ...

Source from : Zawya - 22 days ago


Items Tagged with 'Merck & Co. Inc.'

Phase III stakes are always high. But for Merck & Co. Inc., results of a late-stage test of its SARS-CoV-2 antiviral, molnupiravir, stand to determine not just the fate of a desired emergency use ...

Source from : BioWorld - 21 days ago